Clinical trial NCT01775514: A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics
Official title: Occurrence Rate of Non-Small Cell Lung, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey & Diagnosis and Treatment Characteristics Turkish "Non-Small Cell Lung-Colon-Gastric-Breast (CGB) Cancer and Malignant Melanoma" Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2013-01-25
Enrollment: 32277
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants with non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey

Brief summary: This non-interventional study will assess the occurrence rate of non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey, and the diagnostic methods and treatments used. Data will be collected over 36 months.


Eligibility criteria: Inclusion Criteria:

* Participants diagnosed with non-small cell lung, colon, breast, gastric cancer and melanoma
* Participants who give consent to the collection of their information after the first record and pathological confirmation of their cancer

Exclusion Criteria:

* Participants not living in the city or representative region of the study center

Primary outcomes:
measure: Number of Participants with Malignant Melanoma (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
timeFrame: 36 months
measure: Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate), Defined as New Cases Recorded in the Region in 1 Year Divided by (/) Population of the Region
timeFrame: 36 months
measure: Number of Participants with Colon Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
timeFrame: 36 months
measure: Number of Participants with Breast Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
timeFrame: 36 months
measure: Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
timeFrame: 36 months
Secondary outcomes:
measure: Percentage of Participants Categorized by Tumor Size
timeFrame: 36 months
measure: Percentage of Participants Categorized by Histopathology Diagnosis
timeFrame: 36 months
measure: Percentage of Participants Categorized by the Staging System
timeFrame: 36 months
measure: Percentage of Participants Categorized by Surgery Type
timeFrame: 36 months
measure: Percentage of Participants Categorized by Type of Treatments Administered (ie, Adjuvant and Neoadjuvant Treatments)
timeFrame: 36 months
measure: Percentage of Participants With Metastasis Categorized by Treatment Regimens Used (ie, First-line, Second-line, Third-line, or Forth-line Chemotherapy)
timeFrame: 36 months
measure: Overall Survival (OS)
timeFrame: 36 months
measure: Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
timeFrame: 36 months
measure: Percentage of Participants With Family History of Cancer and Other Conditions
timeFrame: 36 months
measure: Percentage of Participants With History of Another Primary Cancer
timeFrame: 36 months
measure: Percentage of Participants Categorized by Diagnostic Methods
timeFrame: 36 months
measure: Percentage of Participants With Metastasis
timeFrame: 36 months
measure: Percentage of Participants Categorized by Tumor Localization
timeFrame: 36 months
Other outcomes:
Locations:
city: Adana
country: Turkey
city: Adana
country: Turkey
city: Afyon
country: Turkey
city: Ankara
country: Turkey
city: Ankara
country: Turkey
city: Ankara
country: Turkey
city: Ankara
country: Turkey
city: Ankara
country: Turkey
city: Baıkesir
country: Turkey
city: Bursa
country: Turkey
city: Bursa
country: Turkey
city: Denizli
country: Turkey
city: Diyarbakir
country: Turkey
city: Edirne
country: Turkey
city: Erzurum
country: Turkey
city: Gaziantep
country: Turkey
city: Isparta
country: Turkey
city: Istanbul
country: Turkey
city: Istanbul
country: Turkey
city: Istanbul
country: Turkey
city: Istanbul
country: Turkey
city: Istanbul
country: Turkey
city: Izmir
country: Turkey
city: Izmir
country: Turkey
city: Izmir
country: Turkey
city: Kayseri
country: Turkey
city: Konya
country: Turkey
city: Malatya
country: Turkey
city: Sıhhiye, ANKARA
country: Turkey
city: Tokat
country: Turkey
city: Trabzon
country: Turkey
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References: